Stay updated on De-Escalated Radiation + Nivolumab in P16+ Oropharynx Cancer Clinical Trial
Sign up to get notified when there's something new on the De-Escalated Radiation + Nivolumab in P16+ Oropharynx Cancer Clinical Trial page.

Latest updates to the De-Escalated Radiation + Nivolumab in P16+ Oropharynx Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe clinical trial record for adjuvant de-escalated radiation and nivolumab in p16-positive oropharyngeal cancer is now displayed, including eligibility, treatment details, outcomes, and study results. The record identifies the trial as completed and no longer recruiting participants.SummaryDifference85%

- Check16 days agoChange DetectedThe footer revision label was updated from v3.7.2 to v3.8.0. The page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check23 days agoChange DetectedA notice announces NIH’s transition from the term “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check30 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check37 days agoChange DetectedThe site footer now displays revision v3.7.1 instead of v3.7.0 on the 403 error page.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record content. This means the NCT03715946 study details are no longer accessible on the page.SummaryDifference24%

Stay in the know with updates to De-Escalated Radiation + Nivolumab in P16+ Oropharynx Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the De-Escalated Radiation + Nivolumab in P16+ Oropharynx Cancer Clinical Trial page.